Welcome to the Leeds Medicines Formulary |
Useful Links
|
| News Feed |
|
MHRA: Drug Safety Update (Mar 18): daclizumab, Esmya (ulipristal acetate), head lice treatments
|
MHRA: Drug Safety Update (Feb 18): Mysodelle, mycophenolate, contrast agents
|
MHRA: Drug Safety Update: daclizumab, epo, co-dydramol (Jan 18)
|
MHRA: Drug Safety Update (Dec 17): fingolimod, eluxadoline, cladribine + more
|
LTHT: Common alternatives in swallowing difficulties and feeding tubes
|
MHRA: Drug Safety Update (Nov 17): quinine, gentamicin, tacrolimus
|
| >>> more news |
|
The Leeds Formulary aims to provide
information on medicines supporting safe, evidence-based, cost-effective
practice. Whilst the formulary contains links to relevant policies and
guidelines, the prescriber retains the responsibility for the appropriate use
of this information. For further information on the
development of the Leeds Formulary and participating organisations, please
go to our 'About'
page.
Comments about any aspect of the formulary can be made by using the feedback
tab at the top of this page. Updates to the formulary are shared via the
newsfeed above and on the Leeds Medicines Management
Hub on
Leeds Health Pathways. You can also follow us on Twitter -
@LeedsFormulary.
|
|
